Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes
Tóm tắt
Từ khóa
Tài liệu tham khảo
Levey, 2007, Chronic kidney disease: common, harmful and treatable – World Kidney Day 2007, Am J Kidney Dis, 49, 175, 10.1053/j.ajkd.2006.12.013
National Kidney Foundation, 2002, K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification, Am J Kidney Dis, 39, S1
Levey, 2003, National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification, Ann Intern Med, 139, 137, 10.7326/0003-4819-139-2-200307150-00013
Levey, 2005, Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney Int, 67, 2089, 10.1111/j.1523-1755.2005.00365.x
Coresh, 2005, Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000, J Am Soc Nephrol, 16, 180, 10.1681/ASN.2004070539
Stevens, 2006, Assessing kidney function – measured and estimated glomerular filtration rate, N Engl J Med, 354, 2473, 10.1056/NEJMra054415
de Zeeuw, 2005, The kidney, a cardiovascular risk marker and a new target for therapy, Kidney Int Suppl, 98, S25, 10.1111/j.1523-1755.2005.09805.x
Chen, 2005, Prevalence of decreased kidney function in Chinese adults aged 35 to 74 years, Kidney Int, 68, 2839, 10.1111/j.1523-1755.2005.00757.x
Hallan, 2006, International comparison of the relationship of chronic kidney disease prevalence and ESRD risk, J Am Soc Nephrol, 17, 2275, 10.1681/ASN.2005121273
Chadban, 2003, Prevalence of kidney damage in Australian adults: the AusDiab kidney study, J Am Soc Nephrol, 14, S131, 10.1097/01.ASN.0000070152.11927.4A
Keith, 2004, Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization, Arch Intern Med, 164, 659, 10.1001/archinte.164.6.659
National Kidney Foundation, 2003, K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease, Am J Kidney Dis, 41, S1
National Kidney Foundation, 2003, K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease, Am J Kidney Dis, 42, S1
National Kidney Foundation, 2004, K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease, Am J Kidney Dis, 43, S1
National Kidney Foundation, 2006, K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease, Am J Kidney Dis, 47, S1
Chobanian, 2003, The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report, JAMA, 289, 2560, 10.1001/jama.289.19.2560
Sarnak, 2003, Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention, Hypertension, 42, 1050, 10.1161/01.HYP.0000102971.85504.7c
American Diabetes Association, 2006, Standards of medical care in diabetes-2006, Diabetes Care, 29, S1
2005
Yach, 2004, The global burden of chronic diseases: overcoming impediments to prevention and control, JAMA, 291, 2616, 10.1001/jama.291.21.2616
Fried, 2005, Kidney function as a predictor of non-cardiovascular mortality, J Am Soc Nephrol, 16, 3728, 10.1681/ASN.2005040384
Eknoyan, 2004, The burden of kidney disease: improving global outcomes, Kidney Int, 66, 1310, 10.1111/j.1523-1755.2004.00894.x
Mann, 2003, Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study, J Am Soc Nephrol, 14, 641, 10.1097/01.ASN.0000051594.21922.99
Boulware, 2003, Screening for proteinuria in US adults: a cost-effectiveness analysis, JAMA, 290, 3101, 10.1001/jama.290.23.3101
Atthobari, 2006, Cost-effectiveness of screening for albuminuria and subsequent treatment with an ACE inhibitor to prevent cardiovascular events: a pharmacoeconomic analysis linked to the PREVEND and the PREVEND IT studies, Clin Ther, 28, 432, 10.1016/j.clinthera.2006.03.012
Lysaght, 2002, Maintenance dialysis population dynamics: current trends and long-term implications, J Am Soc Nephrol, 13, S37, 10.1681/ASN.V13suppl_1s37
US Renal Data System, 2005
National Kidney Foundation, 2005, K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients, Am J Kidney Dis, 45, S1
McCullough, 2004, Cardiovascular disease in chronic kidney disease from a cardiologist's perspective, Curr Opin Nephrol Hypertens, 13, 591, 10.1097/00041552-200411000-00003
Barsoum, 2004, The changing face of schistosomal glomerulopathy, Kidney Int, 66, 2472, 10.1111/j.1523-1755.2004.66042.x
Altintepe, 2005, Urinary tuberculosis: ten years’ experience, Ren Fail, 27, 657, 10.1080/08860220500234857
Shaheen, 2005, Preventive strategies of renal failure in the Arab world, Kidney Int Suppl, 98, S37, 10.1111/j.1523-1755.2005.09807.x
Shah, 2006, Update on HIV-associated nephropathy, Curr Opin Nephrol Hypertens, 15, 450, 10.1097/01.mnh.0000232887.58271.67
Foley, 2006, Infections and cardiovascular disease in patients with chronic kidney disease, Adv Chronic Kidney Dis, 13, 205, 10.1053/j.ackd.2006.04.006
Jaber, 2005, Bacterial infections in hemodialysis patients: pathogenesis and prevention, Kidney Int, 67, 2508, 10.1111/j.1523-1755.2005.00364.x
Foley, 2004, Septicemia in the United States dialysis population, 1991 to 1999, J Am Soc Nephrol, 15, 1038, 10.1097/01.ASN.0000119144.95922.C4
Allon, 2003, Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study, J Am Soc Nephrol, 14, 1863, 10.1097/01.ASN.0000074237.78764.D1
Sarnak, 2000, Mortality caused by sepsis in patients with end-stage renal disease compared with the general population, Kidney Int, 58, 1758, 10.1111/j.1523-1755.2000.00337.x
Sarnak, 2001, Pulmonary infectious mortality among patients with end-stage renal disease, Chest, 120, 1883, 10.1378/chest.120.6.1883
Gardner, 2003, Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women, J Acquir Immune Defic Syndr, 32, 203, 10.1097/00126334-200302010-00013
Gardner, 2003, Rates and risk factors for condition-specific hospitalizations in HIV-infected and uninfected women, J Acquir Immune Defic Syndr, 34, 320, 10.1097/00126334-200311010-00011
Szczech, 2004, The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection, Kidney Int, 66, 1145, 10.1111/j.1523-1755.2004.00865.x
Szczech, 2004, Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy, Clin Infect Dis, 39, 1199, 10.1086/424013
Levin, 2006, Baseline glomerular filtration rate <60 ml/min is associated with increased mortality among HIV patients on antiviral therapy [abstract], J Am Soc Nephrol., 17, 803A
Fontana, 2002, Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy, Gastroenterology, 123, 719, 10.1053/gast.2002.35352
Tsui, 2006, Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey, J Am Soc Nephrol, 17, 1168, 10.1681/ASN.2005091006
Huang, 2006, Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link?, J Intern Med, 260, 255, 10.1111/j.1365-2796.2006.01686.x
Huang, 1996, Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease, Pharmacotherapy, 16, 222, 10.1002/j.1875-9114.1996.tb02938.x
Noormohamed, 1998, Poor correlation between published methods to predict creatinine clearance and measured creatinine clearance in asymptomatic HIV infected individuals, Ren Fail, 20, 627, 10.3109/08860229809045156
Zeuzem, 2000, Peginterferon alfa-2a in patients with chronic hepatitis C, N Engl J Med, 343, 1666, 10.1056/NEJM200012073432301
Torriani, 2004, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients, N Engl J Med, 351, 438, 10.1056/NEJMoa040842
Gallant, 2006, Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV, N Engl J Med, 354, 251, 10.1056/NEJMoa051871
Gupta, 2005, Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America, Clin Infect Dis, 40, 1559, 10.1086/430257
Cho, 2004, HIV and the kidney: a status report after 20 years, Curr HIV/AIDS Rep, 1, 109, 10.1007/s11904-004-0016-9
Lucas, 2004, Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study, AIDS, 18, 541, 10.1097/00002030-200402200-00022
Grinspoon, 2005, Cardiovascular risk and body-fat abnormalities in HIV-infected adults, N Engl J Med, 352, 48, 10.1056/NEJMra041811
Mehta, 2005, Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population, HIV Clin Trials, 6, 5, 10.1310/HT0W-NX2N-U2BM-7LUU
Morales, 1999, Glomerulonephritis associated with hepatitis C virus infection, Curr Opin Nephrol Hypertens, 8, 205, 10.1097/00041552-199903000-00009
Meyers, 2003, Hepatitis C and renal disease: an update, Am J Kidney Dis, 42, 631, 10.1016/S0272-6386(03)00828-X
2004, American Society of Transplant Surgeons and American Society of Transplantation. Guidelines for vaccination of solid organ transplant candidates and recipients, Am J Transplant, 4, 160, 10.1111/j.1600-6135.2004.00737.x
Dinits-Pensy, 2005, The use of vaccines in adult patients with renal disease, Am J Kidney Dis, 46, 997, 10.1053/j.ajkd.2005.08.032
Kausz, 2006, Overview of vaccination in chronic kidney disease, Adv Chronic Kidney Dis, 13, 209, 10.1053/j.ackd.2006.04.007
Fraser, 1994, Increasing serum creatinine and age reduce the response to hepatitis B vaccine in renal failure patients, J Hepatol, 21, 450, 10.1016/S0168-8278(05)80327-7
DaRoza, 2003, Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better, Am J Kidney Dis, 42, 1184, 10.1053/j.ajkd.2003.08.019
Dash, 2006, Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder, Cancer, 107, 506, 10.1002/cncr.22031
Murray, 2003, Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs, J Clin Oncol, 21, 2633, 10.1200/JCO.2003.04.083
Séronie-Vivien, 2006, Contribution of the MDRD equation and of cystatin C for renal function estimates in cancer patients, Med Oncol, 23, 63, 10.1385/MO:23:1:63
Holweger, 2005, Accurate assessment of individual glomerular filtration rate in cancer patients: an ongoing challenge, J Cancer Res Clin Oncol, 131, 559, 10.1007/s00432-005-0679-7
Lefaucheur, 2006, Membranous nephropathy and cancer: epidemiologic evidence and determinants of high risk cancer association, Kidney Int, 70, 1510, 10.1038/sj.ki.5001790
Launay-Vacher, 2006, Renal insufficiency in cancer patients: prevalence and implications on anticancer drugs management. Results of the ‘IRMA’ study, Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I, 24, 8603
Huang, 2006, Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective study, Lancet Oncology, 7, 735, 10.1016/S1470-2045(06)70803-8
Stewart, 2003, Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand, J Am Soc Nephrol, 14, 197, 10.1097/01.ASN.0000039608.81046.81
Matson, 1990, Acquired cystic kidney disease: occurrence, prevalence, and renal cancers, Medicine, 69, 217, 10.1097/00005792-199007000-00003
Farivar-Mohseni, 2006, Renal cell carcinoma and end-stage renal disease, J Urol, 175, 2018, 10.1016/S0022-5347(06)00340-5
Vajdic, 2006, Cancer incidence before and after kidney transplantation, JAMA, 196, 2823, 10.1001/jama.296.23.2823
Xue, 2005, Cancer prevalence in patients with ESRD [abstract], J Am Soc Nephrol, 16, 726a
Chertow, 1996, Cost effectiveness of cancer screening in end-stage renal disease, Arch Intern Med, 156, 1345, 10.1001/archinte.1996.00440110117016
Irie, 2006, The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population, Kidney Int, 69, 1264, 10.1038/sj.ki.5000284
Lever, 1998, Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?, Lancet, 352, 179, 10.1016/S0140-6736(98)03228-0
Pedersen, 1998, Microalbuminuria in patients with lung cancer, Eur J Cancer, 34, 76, 10.1016/S0959-8049(97)10003-X
Cassidy, 2002, First line oral capecitabine therapy in metastatic colorectal cancer: safety profile compared to intravenous 5-FU/leucovorin, Ann Oncol, 13, 566, 10.1093/annonc/mdf089
Calvert, 2002, Carboplatin dosing formulae: gender bias and the use of creatinine based methodologies, Eur J Cancer, 38, 11, 10.1016/S0959-8049(01)00340-9
Menon, 2007, Risk factors and kidney disease
Kotzmann, 1999, Basal calcitonin levels and the response to pentagastrin stimulation in patients after kidney transplantation or on chronic hemodialysis as indicators of medullary carcinoma, Thyroid, 9, 943, 10.1089/thy.1999.9.943